Table 4 Drug treatment prescribed at baseline (after change) by class
From: The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy
Monotherapy (n = 137) | Co-therapy with 2 drugs (n = 264) | Polytherapy (> 2 drugs) (n = 151) | |||
|---|---|---|---|---|---|
Drug | N (%) | Drugs | N (%) | Drugs | N (%) |
Olanzapine | 69 (50.4) | Olanzapine/Valproate | 59 (22.3) | Olanzapine/Valproate/Lithium | 11 (7.3) |
Valproate | 21 (15.3) | Olanzapine/Lithium | 39 (14.8) | Olanzapine/other AC/Lithium | 10 (6.6) |
Risperidone | 11 (8.0) | Olanzapine/non-valproate AC | 34 (12.9) | Olanzapine/other typicals/Valproate | 8 (5.3) |
Other AC | 10 (7.3) | Risperidone/Valproate | 19 (7.2) | Olanzapine/other typicals/other AC | 7 (4.6) |
Lithium | 9 (6.6) | Other typical/atypical | 16 (6.1) | Olanzapine/other typicals/lithium | 2 (1.3) |
Quetiapine | 6 (4.4) | Risperidone/Lithium | 14 (5.3) | Other combinations | 113 (74.8) |
Haloperidol | 6 (4.4) | Other atypical/Valproate | 11 (4.2) | ||
Other typical | 4 (2.9) | Haloperidol/Lithium | 9 (3.4) | ||
Other atypical | 1 (0.7) | Other atypical/non-valproate AC | 7 (2.7) | ||
Other typical/Lithium | 7 (2.7) | ||||
2 typicals | 7 (2.7) | ||||
Other typical/non-valproate AC | 6 (2.3) | ||||
Risperidone/non-valproate AC | 6 (2.3) | ||||
Other combinations | 30 (11.4) | ||||